3 Hidden-Gem Small-Caps Flying Under Radar in Mid-2026

Everyone's watching chip stocks surge and Samsung crater. Nobody's watching the companies that actually benefit when the world gets messier — and right now, the world is extremely messy. Here are three sub-$10B names worth putting on your radar.

$CRTX — Cortexyme / Quince Therapeutics isn't our pick, but $CRNX (Crinetics Pharmaceuticals) just got acquired by Vertex for $10 billion at a 102% premium, which means the endocrinology/rare disease space is suddenly the hottest M&A hunting ground on the Street. The sleeper here is $ANAB (AnaptysBio), a sub-$1B clinical-stage immunology biotech with two mid-stage assets in inflammatory disease — exactly the profile Vertex just paid double for.

$MFAC (Medallion Financial) is a niche specialty lender flying completely under the radar, while defense infrastructure play $HWKN (Hawkins Inc.) — a specialty chemical distributor with defense and water treatment exposure — has seen quiet institutional accumulation. With NATO members pledging 5% GDP to defense by 2035 and water infrastructure spending accelerating, the picks-and-shovels angle here is genuinely underappreciated.

The biggest hidden gem catalyst of 2026 might just be: everyone chasing AI, nobody watching the boring companies that keep the lights on.